Treatment of the overactive bladder with tolterodine, a new muscarinic receptor antagonist

BJU International, Supplement

Volumn 83, Issue 2, 1999, Pages 48-52

  Messelink, E J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Adverse events; Bladder symptoms; Efficacy; Oxybutynin; Randomized controlled trials; Tolterodine

Indexed keywords

MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; TOLTERODINE;

ADULT; AGED; BLADDER DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; META ANALYSIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RECEPTOR AFFINITY; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; BENZHYDRYL COMPOUNDS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; CRESOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; RANDOMIZED CONTROLLED TRIALS; URINARY BLADDER DISEASES; URINATION DISORDERS;

EID: 0032990888     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. Abrams PH, Blaivas JG, Stanton SL, Andersen JT. Standardisation of terminology of lower urinary tract function. Neurourol Urodynam 1988; 7: 403-27
2. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obst Gyn 1997; 104: 988-93
3. Nilvebrant L, Hallen B, Larsson G. Tolterodine, a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci 1997; 60: 1129-36
4. Nilvebrant L, Andersson KE, Gillberg PG, Stahl M, Sparf B. Tolterodine, a new bladder selective antimuscarinic agent. Eur J Pharmacol 1997; 327: 196-207
5. Brynne N, Stahl MM, Hallen B et al. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharm Ther 1997; 35: 287-95
6. Stahl MM, Ekstrom B, Sparf B, Mattiason A, Andersson KE. Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodynam 1995; 14: 647-55
7. Rentzhog L, Stanton SL, Cardozo L, Nelson E, Fall M, Abrams P. Efficacy and safely of tolterodine in patients with detrusor instability: a dose-ranging study. Br J Urol 1998; 81: 42-8
8. Jonas U, Hofner K, Madersbacher H. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. World J Urol 1997; 15: 144-51
9. Abrams P, Freeman R, Anderström C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998; 81: 801-10
10. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997; 50: 90-6